Sirolimus protein-bound particles is approved for malignant perivascular epithelioid cell tumor

Share This Post

Jan 2022: For adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumours, the Food and Drug Administration licenced sirolimus protein-bound particles for injectable suspension (albumin-bound) (Fyarro, Aadi Bioscience, Inc.) (PEComa).

Efficacy was tested in 31 patients with locally advanced unresectable or metastatic malignant PEComa in AMPECT (NCT02494570), a multicenter, single-arm clinical study. On days 1 and 8 of each 21-day cycle, patients received 100 mg/m2 sirolimus protein-bound particles until disease progression or intolerable toxicity.

Overall response rate (ORR) and duration of response (DOR) were the key efficacy outcome measures, as determined by a blinded independent central review using RECIST v.1.1. The ORR was 39 percent (95 percent CI: 22 percent, 58 percent), with two patients responding completely. The median DOR was not met (95 percent CI: 6.5 months, not estimable). 67 percent of respondents had a response that lasted more than 12 months, and 58 percent had a response that lasted more than 24 months.

Stomatitis, weariness, rash, infection, nausea, edoema, diarrhoea, musculoskeletal discomfort, decreased weight, decreased appetite, cough, vomiting, and dysgeusia were the most prevalent side events (30 percent). Decreased lymphocytes, increased glucose, decreased potassium, decreased phosphate, decreased haemoglobin, and elevated lipase were the most prevalent grade 3 to 4 laboratory abnormalities (6%).

Until disease progression or intolerable toxicity, the recommended dosage is 100 mg/m2 given as an IV infusion over 30 minutes on days 1 and 8 of each 21-day cycle.


Click this link for full prescribing information for Fyarro.

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form